Posted by Michael Wonder on 03 Aug 2023
Jazz Pharmaceuticals enters into letter of intent with the pan-Canadian Pharmaceutical Alliance for Rylaze, helping address the unmet need of acute lymphoblastic leukaemia and lymphoblastic lymphoma patients across Canada
2 August 2023 - Jazz Pharmaceuticals today announced that the Company has entered into a letter of intent with the pan-Canadian Pharmaceutical Alliance regarding Rylaze (crisantaspase recombinant) in Canada.
This allows for individual jurisdictions in Canada to begin formalising access for eligible patients.
